Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 EPS by 16c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q4 EPS of $0.07, $0.16 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $108.45 million versus the consensus estimate of $106.96 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $57 at Guggenheim
• Blue Owl leads $2.4 billion debt deal for Iren data center
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook